Jomed Valve Repair Sale To Edwards Could Presage Additional Divestitures
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences will combine Jomed's catheter-based mitral heart valve repair technology with its own percutaneous R&D program under a two-pronged strategy to address a potential $800 mil. global market for the procedure